Menu

Bioanalytical Pharmacokinetics: The Intrinsic Value of Affimers®

Avacta presents a look at Affimers, and how they are changing R&D for the better.

Dec 12, 2017
The Scientist Creative Services Team

Bioanalytical Pharmacokinetics: The Intrinsic Value of Affimers from thescientistllc on Vimeo.

Antibodies represent the gold standard of affinity reagents used for regulated bioanalysis of therapeutic proteins. Over time, traditional antibodies have been refined to the point where they are specific, sensitive, and reasonably reliable. Yet, antibodies and natural ligands have their limitations and can present challenges with supply, stability and batch-to-batch variation on assay performance. This webinar demonstrates a high-performance Affimer assay detecting and quantifying the breast cancer drug Trastuzumab, showing good sensitivity and increased dynamic range compared to the current antibody-based methods.

Topics to be covered:

  • How antibody variability impedes pharmacokinetic studies
  • What are Affimers, and when to adopt them for your R&D pipeline

Meet the Speakers:

 

Amy Reeves
Assay Development Intern
Covance

 

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.